基于银屑病关节炎外周血辅助性T细胞特征表型选择不同生物制剂DMARDs的精准医学研究
研究纳入64例MTX抵抗的银屑病关节炎患者,其中26例根据8色流式细胞术检测的外周血辅助性T细胞表型选择生物制剂DMARDs治疗,另38例接受标准治疗,6个月时评估疗效。策略性治疗组SDAI、DAS28(ESR)和PASI均显著下降,SDAI低疾病活动度达标率显著高于标准治疗组。
要点
- 基于外周血辅助性T细胞表型选择bDMARDs的策略治疗组6个月SDAI低疾病活动度达标率显著高于标准bDMARDs治疗组。
- 策略性治疗组26例中24例(92.3%)在6个月时达到SDAI低疾病活动度。
- 策略性治疗组SDAI从16.2降至3.52,DAS28(ESR)从4.13降至2.27,PASI从8.36降至2.40。
核心结论
- 根据辅助性T细胞表型差异选择不同bDMARDs的策略性治疗疗效显著高于标准bDMARDs治疗,提示精准医学的价值。
研究设计与样本
- 研究纳入64例MTX抵抗的银屑病关节炎患者,其中26例根据8色流式细胞术检测的外周血辅助性T细胞表型差异接受bDMARDs治疗,另38例接受标准治疗,6个月时评估疗效。
主要发现
- 策略性治疗组26例根据外周血分析分为四型:CXCR3+CCR6-CD38+HLA-DR+活化Th1细胞为主型、CXCR3-CCR6+CD38+HLA-DR+活化Th17细胞为主型、Th1/Th17高型及Th1/Th17低型。
- 活化Th1细胞为主型患者接受乌司奴单抗治疗,活化Th17细胞为主型患者接受司库奇尤单抗治疗,Th1/Th17高型患者接受司库奇尤单抗或TNF抑制剂治疗,Th1/Th17低型患者接受TNF抑制剂治疗。
- 策略性治疗6个月后,SDAI从16.2降至3.52,DAS28(ESR)从4.13降至2.27,PASI从8.36降至2.40,均显著下降。
- 26例中24例(92.3%)达到SDAI低疾病活动度,策略性bDMARDs治疗组6个月时SDAI低疾病活动度达标率显著高于标准bDMARDs治疗组。
关键数值与推荐
- 策略性治疗组26例中24例(92.3%)达到SDAI低疾病活动度。
- 策略性治疗组SDAI从16.2降至3.52,DAS28(ESR)从4.13降至2.27,PASI从8.36降至2.40。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA. METHODS: Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral helper T cells on 8-colour flow cytometry. The efficacies of this strategic treatment and the standard treatment administered to the other 38 patients were evaluated at 6 months. RESULTS: The 26 patients with PsA in the strategic treatment group were classified into the following four types based on peripheral blood analysis: (i) CXCR3+CCR6-CD38+HLA-DR+ activated Th1 cell-predominant type, (ii) CXCR3-CCR6+ CD38+HLA-DR+ activated Th17 cell-predominant type, (iii) Th1/Th17-high type and (iv) Th1/Th17-low type. Accordingly, ustekinumab was administered to the activated Th1 cell-predominant patients, secukinumab to the activated Th17 cell-predominant patients, secukinumab or TNF inhibitor to the Th1/Th17-high patients, and TNF inhibitor to the Th1/Th17-low patients. After 6 months of strategic treatment, there was a significant decrease in simplified disease activity index (SDAI) (from 16.2 to 3.52), DAS28 (ESR) (from 4.13 to 2.27) and psoriasis area and severity index (from 8.36 to 2.40). Low disease activity by SDAI was achieved in 24 (92.3%) of the 26 patients. The rate of low disease activity achievement according to SDAI at 6 months was significantly higher in the strategic bDMARDs treatment group compared with that of the standard bDMARDs treatment group. CONCLUSION: Strategic treatment in which different bDMARDs were selected according to phenotypic differences in helper T cells showed significantly higher efficacy than standard bDMARD therapy, indicating the value of precision medicine.
引用
- Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019. PMID: 29618121. doi:10.1093/rheumatology/key069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。